StockIQ.techAlnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Free AI-powered analysis and research for Alnylam Pharmaceuticals, Inc. stock
Sector: Healthcare
ALNY snapshot
Data as of 3 Nov 2026 close. Updated daily.
Alnylam Pharmaceuticals, Inc. scores 21/100 on StockIQ's model, which reads as strongly negative signals overall. The price is below its 200-day average and at 1% of its 52-week range, down 63.0% over the past year. Latest reported figures show a profit margin of 16.1%, return on equity of 96.6% and revenue growth of +66.9%.
What is driving the score
- Strong Downtrend: -12
- MACD Bearish: -8
- Strong Revenue Growth (66.9%): +8
- Good Profit Margin (16.1%): +5
- High Debt (2.21 D/E): -10
- Strong Liquidity (3.06 Current Ratio): +8
- Excellent ROE (96.6%): +8
- High P/B (17.45): -5
- Long-term Downtrend: -8
- Severe Underperformance (-63.0% over 1 year): -10
- Near 52-Week Low (1%): -5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full ALNY report
Alnylam Pharmaceuticals, Inc. (ALNY) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze ALNY Now →📰 Latest Update
Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says
Fri, October 30, 2026 at 5:00 PM UTC 2 min read
Alnylam Pharmaceuticals received a cautious outlook from UBS, which noted that the company's guidance expectations are on the lower end. Despite this, UBS emphasized that Alnylam's fundamentals remain strong, suggesting potential resilience in its business model. For investors, this indicates that while short-term performance may be tempered, the company's underlying financial health could support future growth opportunities.